Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash from Operations: 2022-2025

Historic Cash from Operations for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to -$65.1 million.

  • Praxis Precision Medicines' Cash from Operations fell 136.57% to -$65.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$228.9 million, marking a year-over-year decrease of 130.02%. This contributed to the annual value of -$131.8 million for FY2024, which is 18.55% down from last year.
  • As of Q3 2025, Praxis Precision Medicines' Cash from Operations stood at -$65.1 million, which was down 18.99% from -$54.7 million recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Cash from Operations ranged from a high of -$20.9 million in Q1 2024 and a low of -$65.1 million during Q3 2025.
  • For the 3-year period, Praxis Precision Medicines' Cash from Operations averaged around -$37.8 million, with its median value being -$31.2 million (2023).
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 48.32% in 2023, then crashed by 154.16% in 2025.
  • Over the past 4 years, Praxis Precision Medicines' Cash from Operations (Quarterly) stood at -$28.8 million in 2022, then grew by 17.17% to -$23.9 million in 2023, then crashed by 135.20% to -$56.1 million in 2024, then tumbled by 136.57% to -$65.1 million in 2025.
  • Its Cash from Operations stands at -$65.1 million for Q3 2025, versus -$54.7 million for Q2 2025 and -$53.0 million for Q1 2025.